+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06282809

Evaluating the Safety of the HistoSonics Edison System Using Histotripsy to Treat Unresectable Pancreatic Adenocarcinoma

Led by HistoSonics, Inc. · Updated on 2026-07-09

50

Participants Needed

1

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety of the HistoSonics Edison System, a device using histotripsy, for destroying pancreatic adenocarcinoma tumors in patients with unresectable locally advanced Stage 3 or oligometastatic Stage 4 pancreatic cancer. This exploratory, interventional trial aims to provide insight into the safety of this non-thermal, mechanical ultrasound treatment for this serious condition. Participants will receive treatment with the HistoSonics Edison System, which uses focused ultrasound to mechanically destroy targeted soft tissue tumors. This single-arm study involves treating only one tumor per participant during the index procedure. Following treatment, imaging will be performed within 36 hours to assess the tumor. Participants will then be followed closely at 7, 14, 30, 60, 120, and 180 days after the procedure. During the study, participants will undergo imaging and clinical assessments at scheduled timepoints to monitor safety and treatment effects. The primary outcome is to evaluate safety within 30 days after the histotripsy procedure. Participants will be monitored through regular follow-up visits up to 180 days post-treatment to assess their condition and any potential adverse effects. The total participation time spans approximately six months from treatment onward.

CONDITIONS

Brief Title

The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy

Research Team

Z

Zoe Secord

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here